EE668 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Adults and Adolescents Aged 12 Years and Older With Resected Stage IIB/IIC Melanoma in France
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.933
https://www.valueinhealthjournal.com/article/S1098-3015(23)04063-9/fulltext
Title :
EE668 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Adults and Adolescents Aged 12 Years and Older With Resected Stage IIB/IIC Melanoma in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04063-9&doi=10.1016/j.jval.2023.09.933
First page :
Section Title :
Open access? :
No
Section Order :
10427